OSL Biotech has not received much attention on social media whilst progressing . With recent regulatory approval in switzerland where it can now sell as well as the European Union , UK , Malaysia and New Zealand where it achieved its first sale not long ago . First Sales expected to come from Europe this year . Already submitted HDE application for Bile Duct Cancer in the United States and if successful this is going to be major step forward into the US Market . Decision due this quarter or the next . Well funded with around $ 20 million cash and Directors on market trade of $ 405 000 is also a good sign of confidence .
